Notification of Major Interest in Mediclinic International plc shares Mediclinic International plc (Incorporated in England and Wales) Company Number: 08338604 LSE Share Code: MDC JSE Share Code: MEI NSX Share Code: MEP ISIN: GB00B8HX8Z88 LEI: 2138002S5BSBIZTD5I60 (“Mediclinic”, the “Company” or the “Group”) 7 November 2018 Notification of Major Interest in Mediclinic International plc shares 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: MEDICLINIC INTERNATIONAL PLC 1b. Please indicate if the issuer is a non-UK issuer (please mark with an “X” if appropriate) Non-UK issuer 2. Reason for the notification (please mark the appropriate box or boxes with an “X”) An acquisition or disposal of voting rights X An acquisition or disposal of financial instruments An event changing the breakdown of voting rights Other (please specify): 3. Details of person subject to the notification obligation Name PUBLIC INVESTMENT CORPORATION SOC LIMITED City and country of registered office (if applicable) PRETORIA, SOUTH AFRICA 4. Full name of shareholder(s) (if different from 3.) Name City and country of registered office (if applicable) 5. Date on which the threshold was crossed or reached: 06/11/2018 6. Date on which issuer notified (DD/MM/YYYY): 07/11/2018 7. Total positions of person(s) subject to the notification obligation % of voting rights % of voting rights Total number of attached to shares through financial in- Total of both in % voting rights of (total of 8. A) struments (8.A + 8.B) issuer (total of 8.B 1 + 8.B 2) Resulting situation on the date on which threshold was crossed or reached 8.149% 8.149% 737 243 810 Position of previous notification (if applicable) 7.989% 7.989% 8. Notified details of the resulting situation on the date on which the threshold was crossed or reached A: Voting rights attached to shares Number of voting rights % of voting rights Indirect Indirect Class/type of Direct (Art 10 of Directive Direct (Art 10 of Directive shares (Art 9 of Directive 2004/109/EC) (Art 9 of Directive 2004/109/EC) ISIN code (if possible) 2004/109/EC) (DTR5.1) (DTR5.2.1) 2004/109/EC) (DTR5.1) (DTR5.2.1) 60 077 807 8.149% SUBTOTAL 8. A 60 077 807 8.149% B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a)) Number of voting rights that may be acquired if Type of financial Expiration Exercise/ the instrument is instrument date Conversion Period exercised/converted. % of voting rights SUBTOTAL 8. B 1 NIL NIL B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b)) Exercise/ Physical or Type of financial Expiration Conversion cash Number of instrument date Period settlement voting rights % of voting rights SUBTOTAL 8.B.2 NIL NIL 9. Information in relation to the person subject to the notification obligation (please mark the applicable box with an “X”) Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entity (please add additional rows as necessary) % of voting rights % of voting rights if it through financial in- Total of both if it equals or is higher struments if it equals equals or is higher than the notifiable or is higher than the than the notifiable Name threshold notifiable threshold threshold PUBLIC INVESTMENT CORPORATION SOC LIMITED 8.149% 8.149% 10. In case of proxy voting, please identify: Name of the proxy holder N/A The number and % of voting rights held N/A The date until which the voting rights will be held N/A 11. Additional information Name: DEVILLIERS MAKONKO E-Mail: Devilliers.Makonko @pic.gov.za TEL: +27 12 742 3578 Place of completion PRETORIA, SOUTH AFRICA Date of completion 07 November 2018 Mediclinic has a primary listing on the Main Market of the LSE in the United Kingdom, with secondary listings on the JSE in South Africa and the NSX in Namibia. For further information, please contact: Company Secretary, Link Company Matters Limited Jayne Meacham / Caroline Emmet +44 (0)20 7954 9569 Investor Relations, Mediclinic International plc James Arnold, Head of Investor Relations ir@mediclinic.com +44 (0)20 3786 8181 Media queries FTI Consulting Brett Pollard/Debbie Scott – UK +44 (0)20 3727 1000 Sherryn Schooling – South Africa +27 (0)21 487 9000 Registered address: 6th Floor, 65 Gresham Street, London, EC2V 7NQ, United Kingdom Website: www.mediclinic.com Joint corporate brokers: Morgan Stanley & Co International plc and UBS Investment Bank JSE sponsor: Rand Merchant Bank (A division of FirstRand Bank Limited) NSX sponsor: Simonis Storm Securities (Pty) Ltd Date: 07/11/2018 03:30:00 Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE'). The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct, indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on, information disseminated through SENS.